Thursday September 22, 2022
Notice of R&D Update Meeting
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of R&D Update Meeting Brighton, United Kingdom – 22 September 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on […]
Friday September 9, 2022
Exercise of Options and Total Voting Rights
Exercise of Options and Total Voting Rights Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, […]
Thursday September 8, 2022
Interim results for six months ended 30 June 2022
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.
Thursday September 8, 2022
Interim results for six months ended 30 June 2022
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.
Wednesday September 7, 2022
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Inves...
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines […]
Wednesday September 7, 2022
Positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans
Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans EMA endorses Destiny Pharma’s proposed single pivotal Phase 3 study design for the development […]
Wednesday September 7, 2022
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Inves...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference Brighton, United Kingdom – 7 September 2022 – […]
Wednesday September 7, 2022